Clinical trials: Botulinum toxin type A
Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
- Trial name
- C-BEOND (NCT06047444)
- Testing
- Botulinum toxin type A
- Where
- 120 sites in United States, Canada and 7 more
- Volunteers
- 759 people
- Sponsor
- Ipsen
Migraine
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
- Trial name
- NCT05016661
- Testing
- ABP-450
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 466 people
- Sponsor
- AEON Biopharma, Inc.
Healthy
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relaxation of the injected muscle.
- Trial name
- NCT00694148
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Lower Limb Spasticity
RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke
The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity.
- Trial name
- RELIEF (NCT02020980)
- Testing
- Botulinum toxin type A
- Where
- 28 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Ipsen
Glabellar Lines
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05496335
- Testing
- AGN-151586, BOTOX
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- AbbVie
Crow's Feet Lines
MEDITOXIN® in Treatment of Crow's Feet Line
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
- Trial name
- NCT03317574
- Testing
- botulinum toxin type A
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Spastic Hemiparesis
Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)
The purpose of this clinical study is to assess whether AbobotulinumtoxinA (Dysport®) injections in upper and lower limbs accompanied with a personal exercise plan called "Guided Self-rehabilitation Contract" (GSC) can improve…
- Trial name
- ENGAGE (NCT02969356)
- Testing
- Botulinum toxin type A, GSC
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 157 people
- Sponsor
- Ipsen
Migraine Disorders
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.
- Trial name
- NCT03193346
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Habitual Snoring
Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring
The purpose of this study is to identify out of up to three doses a safe and effective dose of Botulinum toxin type A for an injection into one side of the soft palate to treat snoring.
- Trial name
- NCT01515371
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Hemifacial Spasm
Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.
- Trial name
- NCT00276315
- Testing
- Botulinum toxin type A
- Where
- 4 sites in China
- Volunteers
- 332 people
- Sponsor
- Ipsen
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770211
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States
- Volunteers
- 271 people
- Sponsor
- Merz Pharmaceuticals GmbH
Facial Rhytides
A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides
This is a safety and efficacy study of BOTOX® in subjects with facial rhytides (glabellar lines and crow's feet lines).
- Trial name
- NCT01777620
- Testing
- onabotulinumtoxinA, Normal Saline
- Where
- Canada
- Volunteers
- 125 people
- Sponsor
- Allergan
Urinary Bladder, Overactive
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary…
- Trial name
- NCT03043287
- Testing
- onabotulinumtoxinA
- Where
- 3 sites in United States
- Volunteers
- 420 people
- Sponsor
- Allergan
Myofascial Pain Syndromes
A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.
The purpose of this study is to determine whether electrical stimulation enhances the effect of botulinum toxin type A (Dysport®) on myofascial pain syndrome.
- Trial name
- NCT00246142
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Ipsen
Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM).
- Trial name
- EVEC (NCT05284019)
- Testing
- Eptinezumab, Erenumab, Onabotulinumtoxin-A
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lundbeck A/S
Cervical Dystonia
Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia
The goal of this retrospective, international, multi-center chart abstraction is to learn about the long-term impact of product-specific immunogenicity-related factors in different botulinum neurotoxin type A formulations in…
- Trial name
- RELY-CD (NCT05884528)
- Testing
- CC BoNT/A, CF BoNT/A, CF to CC BoNT/A
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Merz Therapeutics GmbH